क्लोपिडोग्रेल के इंटरैक्शन

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (इट्राकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Antiplatelets: ticagrelor ↑ ticagrelor Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. clopidogrel ↓ clopidogrel active metabolite Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. (एटाज़ानाविर लेबल, दवाओं के इंटरैक्शन)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (एडोक्साबैन लेबल, बॉक्स्ड चेतावनी)

…hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between… (एनोक्सापैरिन लेबल, बॉक्स्ड चेतावनी)

…hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (एपिक्साबैन लेबल, बॉक्स्ड चेतावनी)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (एब्रोसिटिनिब लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Antiplatelets: ticagrelor ↑ ticagrelor Coadminstration with ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Coadministration with clopidogrel is not recommended due to protential reduction of the antiplatelet activity of clopidogrel. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Clopidogrel: Do not administer during KENGREAL infusion. (कैंग्रेलोर लेबल, दवाओं के इंटरैक्शन)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). (टिकाग्रेलोर लेबल, बॉक्स्ड चेतावनी)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (डैबिगैट्रान लेबल, बॉक्स्ड चेतावनी)

Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID. cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. (निर्माट्रेल्विर और रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

…TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). (प्रासुग्रेल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (फेरिक साइट्रेट लेबल, दवाओं के इंटरैक्शन)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between… (फोंडापैरिनक्स लेबल, बॉक्स्ड चेतावनी)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Coadministration of bupropion hydrochloride extended-release tablets (XL) with ticlopidine or clopidogrel is not recommended (7.1). (ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (रिवारोक्साबैन लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use of repaglinide with Plavix. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Celecoxib 100 mg twice daily was non-inferior to naproxen 375 to 500 mg twice daily and ibuprofen 600 to 800 mg three times daily for the composite endpoint of the Antiplatelet Trialists' Collaboration (APTC), which consists of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, and non-fatal stroke [ see Clinical Studies (14.5)… (सेलेकॉक्सिब लेबल, चेतावनियां और सावधानियां)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (आइकोसापेंट एथिल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (एनाग्रेलाइड लेबल, चेतावनियां और सावधानियां)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (एपोप्रोस्टेनोल लेबल, दवाओं के इंटरैक्शन)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (एल्टेप्लेज़ लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

एंटीकोएगुलेंट या एंटीप्लेटलेट दवाओं के साथ लेने पर जिन्कगो ब्लीडिंग का जोखिम बढ़ा सकता है। (NCCIH, Ginkgo)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (टेनेक्टेप्लेज़ लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (ट्रैज़ोडोन लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Concomitant Treatment with CYP2B6 Inhibitors (e.g., ticlopidine or clopidogrel) can increase bupropion exposure. (नाल्ट्रेक्सोन और ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (पेंटोक्सिफाइलिन लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antiplatelets Ticagrelor Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. (मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

विटामिन E प्लेटलेट के आपस में जुड़ने (एग्रीगेशन) और विटामिन K पर निर्भर क्लॉटिंग को रोक सकता है, जिससे एंटीकोएगुलेंट और एंटीप्लेटलेट दवाओं के साथ ब्लीडिंग का जोखिम बढ़ता है। (NIH Office of Dietary Supplements, Vitamin E)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (वोर्टियोक्सेटिन लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Opioids: Decreased exposure to clopidogrel. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (क्लोपिडोग्रेल लेबल, चेतावनियां और सावधानियां)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

If possible, assess the presence of drug-dependent antiplatelet antibodies. (एथोसक्सिमाइड लेबल, चेतावनियां)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

ओमेगा-3 सप्लीमेंट ब्लीडिंग टाइम को हल्का-सा बढ़ा सकते हैं; वारफेरिन जैसे एंटीकोएगुलेंट के साथ इस संयोजन में निगरानी उचित है, हालांकि चिकित्सकीय रूप से महत्वपूर्ण ब्लीडिंग लगातार एक जैसी नहीं दिखाई गई है। (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

लहसुन के सप्लीमेंट वारफेरिन जैसे एंटीकोएगुलेंट के साथ ब्लीडिंग का जोखिम बढ़ा सकते हैं। (NCCIH, Garlic)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZISTA/ritonavir and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZISTA/ritonavir and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel active metabolite… (डारुनाविर लेबल, दवाओं के इंटरैक्शन)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZCOBIX or PREZCOBIX PED and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZCOBIX or PREZCOBIX PED with clopidogrel is not recommended due to the potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel… (डारुनाविर और कोबिसिस्टैट लेबल, दवाओं के इंटरैक्शन)

Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)